Tarceva Advisory Committee To Focus On Treatment Alternatives, Subgroup Concerns

ODAC will review currently available treatment options and negative treatment effects in subgroups as OSI seeks to expand Tarceva's indication to first-line maintenance and monotherapy in NSCLC.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet